Restriction of hepatitis B virus replication by c-Abl–induced proteasomal degradation of the viral polymerase

About 257 million people with chronic infection of hepatitis B virus (HBV) worldwide are at high risk of developing terminal liver diseases. Reactivation of virus replication has been frequently reported in those patient populations receiving imatinib (an Abl kinase inhibitor) or bortezomib (a prote...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Lidan, Zhao, Jie, Gao, Shaobing, Ji, Tong, Song, Tianyu, Li, Yining, Wang, Jingjie, Geng, Chenlu, Long, Min, Chen, Jiang, Lin, Hui, Cai, Xiujun, Cang, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365112/
https://www.ncbi.nlm.nih.gov/pubmed/30775435
http://dx.doi.org/10.1126/sciadv.aau7130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365112/
https://www.ncbi.nlm.nih.gov/pubmed/30775435
http://dx.doi.org/10.1126/sciadv.aau7130

Ejemplares similares